Gritstone bio Inc. (GRTS): חוב להון עצמי

The market price visualization for Gritstone bio, Inc. (GRTS) demonstrates a total debt-to-equity ratio of 4.48. Gritstone bio, Inc. (GRTS) develops personalized cancer vaccines, leveraging the expertise of leading immunologists dedicated to creating innovative medicines. Such research remains independent of economic cycles or inflation, reflecting stable demand. The firm's environmental policy is limited to laboratory safety controls and office recycling.

This indicator measures the ratio of debt to equity, determining the business's degree of financial independence and default risk. By analyzing the debt-to-equity chart, an investor can see the critical dependence of Gritstone bio, Inc. (GRTS) on creditors, which, under the conditions of debt restructuring during bankruptcy, makes any funding for vaccine clinical trials extremely limited and risky.